Yuexiu Group
VC Fund
Wan Chai, Hong Kong
Yuexiu Group is a VC fund in Wan Chai focused on Biotechnology and Genetics. Yuexiu Group was established in Hong Kong in 1985. After more than 30 years of reform and development, the Group has formed a “4+X” modern industrial system with financial, real estate, transportation infrastructure, urban agriculture as its core industry, traditional industries such as papermaking and development, and strategic emerging industriesthat may enter in the future.As of the end of June 2019, the Group's total assets exceeded RMB 630 billion. In the first half of 2019, the Group achieved operating income of RMB 33.2 billion and total profit of RMB 8.9 billion. It is estimated that the total annual profit and tax will be approximately RMB 23 billion. Among them, the total assets of the main business accounted for about 96%, the revenue accounted for about 95%, and the profit contribution accounted for about 98%.Yuexiu Group controls five listed companies including Yuexiu Jinkong, Chong Hing Bank, Yuexiu Real Estate, Yuexiu Transportation Infrastructure and Yuexiu Housing Fund. The Group's overall asset securitization rate is approximately 95%.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Yuexiu Group invests in
Stages Yuexiu Group invests in
Countries Yuexiu Group invests in
Investment Focus
Industry
- Biotechnology 2 (67%)
- Genetics 1 (33%)
- Consulting 1 (33%)
- Construction 1 (33%)
- Therapeutics 1 (33%)
Stage
- Angel 1 (33%)
- Series C 1 (33%)
- Series D 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
IMPACT Therapeutics
|
IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more thanfour decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology. | Series D / Mar 14, 2022 | |
Yikon Genomics
|
Yikon Genomics is a leading solution-based single cell sequencing company. Currently based on the patented MALBAC® technology from Harvard University, Yikon provides complete solutions in the fields of reproductive health and cancer diagnostics with liquid tumor biopsy. The MALBAC-PGS™ and MALBAC-PGD™ solutions offer the most accurate andcomprehensive embryo testing results for physicians to choose the best embryos with balanced chromosomal copy numbers,without inheriting the known disease-associated alleles. The MALBAC-PGS™ and MALBAC-PGD™ solutions have helped thousands of couples to achieve successful pregnancies. Yikon will continue to interpret the code of life and bring people the hope and joy of life. | $31M / Series C / Nov 04, 2019 | |
Guangzhou Metro Design & Research Institute Co., Ltd.
|
Guangzhou Metro Design & Research Institute Co., Ltd. engages in the design and consulting of urban rail transit. | $425K / Angel / May 29, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Yuexiu Group invest in?
Yuexiu Group invests primarily in Biotechnology, Genetics and Consulting startups, most often at Angel and Series C stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Yuexiu Group last invest?
The most recent investment recorded for Yuexiu Group closed in Mar 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
